Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Arthrosi Therapeutics

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: Cohort 2: AR882 or placebo; Drug: Cohort 3: AR882 or placebo; Drug: Cohort 1: AR882 or placebo; Drug: Cohort 4: AR882 or placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04314986

AR882-102

Details and patient eligibility

About

A study to assess multiple ascending doses of AR882 in healthy adult males.

Enrollment: 30 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Screening serum uric acid level ≥ 4.5 mg/dL (268 µmol/L) and < 9 mg/dL (535 µmol/L)
• Body weight no less than 50 kg and body mass index (BMI) within the range of ≥18 and ≤33 kg/m2
• Must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures

Exclusion criteria

• Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin
• History of cardiac abnormalities
• History and/or presence of drug addiction or excessive use of alcohol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

30 participants in 5 patient groups, including a placebo group

AR882 (Dose A)

Experimental group

Treatment:

Drug: Cohort 1: AR882 or placebo

AR882 (Dose B)

Experimental group

Treatment:

Drug: Cohort 2: AR882 or placebo

AR882 (Dose C)

Experimental group

Treatment:

Drug: Cohort 3: AR882 or placebo

AR882 (Dose D)

Experimental group

Treatment:

Drug: Cohort 4: AR882 or placebo

Placebo

Placebo Comparator group

Treatment:

Drug: Cohort 3: AR882 or placebo

Drug: Cohort 1: AR882 or placebo

Drug: Cohort 2: AR882 or placebo

Drug: Cohort 4: AR882 or placebo